(Reuters) – Viridian Therapeutics said on Tuesday its experimental drug to treat patients with thyroid eye disease significantly reduced bulging of the eye in a late-stage study.
Shares of the company were up 6.4% in volatile premarket trading.
Thyroid eye disease is an autoimmune disorder that causes inflammation and damage to the tissues around the eye.
The drug, veligrotug, was generally well-tolerated with no treatment-related serious side-effects, the company said.
(Reporting by Mariam Sunny in Bengaluru; Editing by Shilpi Majumdar)
Brought to you by www.srnnews.com
